Pharvaris (NASDAQ:PHVS) Insider Sells $210,380.05 in Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Peng Lu sold 7,001 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $30.05, for a total transaction of $210,380.05. Following the transaction, the insider directly owned 66,083 shares of the company’s stock, valued at $1,985,794.15. The trade was a 9.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Peng Lu also recently made the following trade(s):

• On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total transaction of $3,003.00.

Pharvaris Trading Up 5.0%

PHVS traded up $1.37 during trading on Friday, hitting $28.66. 94,448 shares of the company traded hands, compared to its average volume of 171,838. The company has a market cap of $1.87 billion, a PE ratio of -8.53 and a beta of -2.58. The stock’s 50-day simple moving average is $27.39 and its two-hundred day simple moving average is $25.80. Pharvaris N.V. has a 1 year low of $14.59 and a 1 year high of $30.24.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Equities analysts expect that Pharvaris N.V. will post -3.19 EPS for the current year.

Institutional Investors Weigh In On Pharvaris

Several institutional investors have recently made changes to their positions in the company. General Atlantic L.P. lifted its holdings in shares of Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after acquiring an additional 500,000 shares during the last quarter. Foresite Capital Management IV LLC lifted its holdings in Pharvaris by 8.3% during the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after buying an additional 368,000 shares in the last quarter. venBio Partners LLC lifted its holdings in Pharvaris by 8.2% during the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after buying an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. lifted its holdings in Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after buying an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP lifted its holdings in Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after buying an additional 507,043 shares in the last quarter.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Royal Bank Of Canada dropped their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Wall Street Zen cut shares of Pharvaris from a “sell” rating to a “strong sell” rating in a research note on Monday, April 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday. Citigroup reissued a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Finally, Wolfe Research started coverage on shares of Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective for the company. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pharvaris currently has an average rating of “Moderate Buy” and a consensus price target of $42.73.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.